Nanovaccines for cancer immunotherapy:Current knowledge and future perspectives  

作　　者：Yiming Wu Zhe Zhang Yuquan Wei Zhiyong Qian Xiawei Wei 

机构地区：[1]Laboratory of Aging Research and Cancer Drug Target,State Key Laboratory of Biotherapy and Cancer Center,National Clinical Research Center for Geriatrics,West China Hospital,Sichuan University,Chengdu 610041,China

出　　处：《Chinese Chemical Letters》2023年第8期57-68,共12页中国化学快报（英文版）

基　　金：supported by the National Science Foundation for Excellent Young Scholars(No.32122052);National Natural Science Foundation Regional Innovation and Development(No.U19A2003).

摘　　要：Cancer immunotherapy harnesses the immune system to attack tumors and has received extensive attention in recent years.Cancer vaccines as an important branch of immunotherapy are designed for delivering tumor antigens to antigen-presenting cells(APCs)to stimulate a strong immune response to against tumors,representing a potentially therapeutic and prophylactic effect with the long-term anticancer benefits.Nevertheless,the disappointing outcomes of their clinical use might be attributed to dilemma in antigen selection,immunogenicity,lymph nodes(LNs)targeting ability,lysosomal escape ability,immune evasion,etc.Nanotechnology,aiming to overcome these barriers,has been utilized in cancer vaccine development for decades.Numerous preclinical and clinical studies demonstrate positive results in nanomaterials-based cancer vaccines with considerable improvement in the vaccine efficacy.In this review,we systematically introduced the characteristics of nanovaccines and highlighted the different types of nanomaterials used for cancer vaccine design.In addition,the opportunities and challenges of the emerging nanotechnology-based cancer vaccines were discussed.

关 键 词：Cancer immunotherapy Cancer vaccines NANOPARTICLES Antitumor immune response Clinical transformation 

分 类 号：TQ464[化学工程—制药化工]